Trial Profile

A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 07 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Hydromethylthionine mesylate (Primary)
Indications Dementia
Focus Registrational; Therapeutic Use
Sponsors TauRx Therapeutics

Most Recent Events

19 May 2020 According to a TauRx Pharmaceuticals media release, results are published in Journal of Alzheimer's Disease (https://doi.org/10.3233/JAD-191173)
19 May 2020 Results published in the Media Release
22 Jul 2016 According to a TauRx Pharmaceuticals media release, the results from this study will be presented at the 10th International Conference on Frontotemporal Dementias (ICFTD).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com